Inventors:
Sylvia Lee-Huang - New York NY, US
Paul L. Huang - Boston MA, US
Philip Lin Huang - Maple Glen PA, US
Dawei Zhang - Elmhurst NY, US
John Z.H. Zhang - New York NY, US
Young Tae Chang - New York NY, US
Jae Wook Lee - San Diego CA, US
Ju Bao - Brooklyn NY, US
Yongtao Sun - Chaanxi Province, CN
International Classification:
A61K 36/00, A61K 31/351, A61K 31/70, A61K 38/28, A61K 31/4439, A61K 31/435, A61K 31/366, A61K 31/7036, A61P 3/00, A61P 31/12, A61K 31/175, A61K 31/445, A61K 31/404, A61K 31/40, A61K 31/427, A61K 31/155, A61K 31/05
US Classification:
424774, 514460, 514734, 514 27, 514636, 514 4, 514369, 514342, 514423, 514277, 514419, 514635, 514634, 514331, 514 42, 514592
Abstract:
The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues.